Get started
DAIHAN PHARMACEUTICALDD

DAIHAN PHARMACEUTICAL

28,400KRWD
+50+0.18%
At close at May 30, 07:44 GMT
KRW
No trades
See on Supercharts
Overview
Financials
Discussions Technicals Seasonals

023910 fundamentals

Key facts

Market capitalization‪170.40 B‬KRW
Dividend yield (indicated)3.17%
Price to earnings Ratio (TTM)5.03
Basic EPS (TTM)5,635.86KRW
Founded1945
Employees (FY)675
CEOYoon-Woo Lee
Websitedaihan.com
About

Daihan Pharmaceutical Co., Ltd. engages in the manufacture and sale of medical products. The company operates through Pharmaceutical products and Other. Its main products include sap ample and contract research services. The company was founded by In-Sil Lee in 1945 and is headquartered in Seoul, South Korea.

Ownership
‪‪5.88 M‬‬
Free Float shares
‪‪3.44 M‬‬ (58.44%)
Closely held shares
‪‪2.44 M‬‬ (41.56%)
Free Float shares
‪‪3.44 M‬‬ (58.44%)
Closely held shares
‪‪2.44 M‬‬ (41.56%)
Capital structure
Market cap
‪‪170.40 B‬‬
Debt
‪‪40.55 M‬‬
Cash & equivalents
‪‪107.01 B‬‬
Enterprise value
‪‪63.43 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪170.40 B‬‬
Price to earning ratio (P/E)
5.03x
Price to sales ratio (P/S)
0.81x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
5.03x
Price to sales ratio (P/S)
0.81x
Valuation ratios
‪0.00‬
‪0.21‬
‪0.42‬
‪0.63‬
‪0.84‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪1.50‬
‪3.00‬
‪4.50‬
‪6.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪15.0%‬
‪15.7%‬
‪16.4%‬
‪17.1%‬
‪17.8%‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪15.00 B‬‬
‪‪30.00 B‬‬
‪‪45.00 B‬‬
‪‪60.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪13.00 B‬‬
‪‪26.00 B‬‬
‪‪39.00 B‬‬
‪‪52.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪13.00 B‬‬
‪‪26.00 B‬‬
‪‪39.00 B‬‬
‪‪52.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Liquid Products
Ampoule and Vial
Other
Testing and Inspection
By country
Period: 2024
South Korea

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪15.00 B‬‬
‪‪30.00 B‬‬
‪‪45.00 B‬‬
‪‪60.00 B‬‬
Actual
Estimate
Earnings
Next:Mar 25, 2026
2021
2022
2023
2024
2025
‪0.00‬
‪‪1.50 K‬‬
‪‪3.00 K‬‬
‪‪4.50 K‬‬
‪‪6.00 K‬‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
15.97%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
3.17%
Last payment
900.00
Last ex-date
Dec 27, 2024
Last pay date
Apr 17, 2025
Dividend history
‪1.0%‬
‪1.7%‬
‪2.4%‬
‪3.1%‬
‪3.8%‬
2020
2021
2022
2023
2024
‪0.00‬
‪250.00‬
‪500.00‬
‪750.00‬
‪‪1.00 K‬‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪20.00 B‬‬
‪‪40.00 B‬‬
‪‪60.00 B‬‬
‪‪80.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪45.00 B‬‬
‪‪90.00 B‬‬
‪‪135.00 B‬‬
‪‪180.00 B‬‬
Assets
Liabilities